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Abstract 
Background 
T-cell infiltration in ER-negative breast tumours has been associated with longer survival.  To 
investigate this association and the potential of tumour T-cell infiltration as a prognostic and 
predictive marker, we have conducted the largest study of T-cells in breast cancer to date. 
Patients and methods 
Four studies totalling 12,439 patients were used for this work.  Cytotoxic (CD8+) and regulatory 
(FOXP3+) T-cells were quantified using immunohistochemistry (IHC).  IHC for CD8 was conducted 
using available material from all four studies (8,978 samples) and for FOXP3 from three studies 
(5,239 samples); multiple imputation was used to resolve missing data from the remaining patients.  
Cox-regression was used to test for associations with breast cancer-specific survival.   
Results 
In ER-negative tumours (triple negative breast cancer and HER2-positive), presence of CD8+ T-cells 
within the tumour was associated with a 28% (95% CI, 16% - 38%) reduction in the  hazard of breast 
cancer-specific mortality, and CD8+ T-cells within the stroma with a 21% (95% CI, 7% - 33%) 
reduction in hazard.  In ER-positive HER2-positive tumours, CD8+ T-cells within the tumour were 
associated with a 27% (95% CI, 4% - 44%) reduction in hazard. In ER-negative disease there was 
evidence for greater benefit from anthracyclines in the NEAT trial in patients with CD8+-positive 
tumours (hazard ratio = 0.54; 95% CI, 0.37-0.79) versus CD8+-negative tumours (hazard ratio  = 0.87; 
95% CI, 0.55-1.38).  The difference in effect between these subgroups was significant when limited to 
cases with complete data (Pheterogeneity=0.04) and approached significance in imputed data 
(Pheterogeneity=0.1).  
Conclusions  
The presence of CD8+ T-cells in breast cancer is associated with a significant reduction in the relative 
risk of death from disease in both the ER-negative and the ER-positive HER2-positive subtypes.  
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Tumour lymphocytic infiltration may improve risk-stratification in breast cancer patients classified 
into these subtypes.  
Key words: breast cancer, lymphocytes, inflammation, chemotherapy, molecular subtypes  
NEAT trial ClinicalTrials.gov number, NCT00003577 
Key message 
We have conducted the largest study of the prognostic and predictive value of tumour infiltrating T-
cells in breast cancer including over 12,000 patients.  CD8+ cytotoxic T-cells in breast tumours are 
associated with a reduced risk of death from breast cancer in ER-negative (HER2-positive and 
negative) and ER-positive HER2-positive breast cancer but not in ER-positive HER2-negative breast 
cancer.      
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Introduction 
The importance of lymphocytic infiltration in predicting disease progression has been shown in 
different types of solid tumour but most impressively in colorectal and ovarian cancer where the 
presence of tumour infiltrating T-cells is associated with reduced recurrence rates and longer 
survival[1, 2].  Moreover, modulation of the T-cell response has shown clinical efficacy in solid 
tumours[3] and the tumouricidal effect of trastuzumab has been shown to depend upon the immune 
response in breast cancer[4].  As a major component of the adaptive immune system, cytotoxic CD8+ 
T-cells represent a candidate biomarker of the tumour-associated immune response.  Most previous 
studies of CD8+ T-lymphocytes in breast cancer have reported an association with favourable 
outcome[5-7] but others have not[8].  Unlike CD8+ T-lymphocytes, T-regulatory lymphocytes (T-
regs) exert an immunosuppressive effect by diminishing the response to self-antigens.  Therefore 
tumours may hijack this function of T-regs to create an immune-privileged niche to facilitate 
unimpeded tumour growth[9].  Nuclear expression of forkhead box protein 3 (FOXP3) characterises 
T-regs.  The presence of FOXP3+ T-lymphocytes in breast tumours has been associated with both 
reduced survival[10] and improved survival[11].    In addition to their association with survival, some 
reports have also found a link between the presence of immune cells and the effect of 
chemotherapy[12, 13]. 
We have investigated the importance of cytotoxic (CD8+) and regulatory (FOXP3+) T-cells in breast 
tumours by conducting a study of over 12,000 patients from the U.K. and Canada.  Our aims were to 
characterise the effect of these subsets of T-lymphocytes on survival, to determine whether this effect 
is modified by the molecular subtype of the primary tumour and to establish whether lymphocytic 
infiltration influenced the effect of chemotherapy on breast cancer mortality. 
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Methods 
Ethics statement and study populations 
We used data from three observational studies of newly diagnosed breast cancer (SEARCH[14], 
N=4,079; BCCA[5], N=4,520; NBCS[6], N=1,842) and one randomised controlled trial (NEAT[15], 
N=1,998 composed of both NEAT (N=1,684) and BR9/601 (N=314)) of breast cancer.  Analyses of 
T-cell data from two of these studies have been published previously[5, 6, 10].  All participating 
studies were approved by the relevant research ethics committee.  SEARCH is a prospective 
population-based study of women diagnosed with breast cancer in East Anglia, England.  The British 
Columbia Cancer Agency (BCCA) study comprised women diagnosed with breast cancer between 
1986 and 1992 in British Columbia and referred to BCCA for consideration of adjuvant therapy.  The 
Nottingham Tenovus Primary Breast Cancer Series (NBCS) comprises patients diagnosed and treated 
at Nottingham City Hospital between 1987 and 1998.  Details of the National Epirubicin Adjuvant 
Trial and BR9601 trial (here collectively referred to as NEAT) have been published previously[15].  
Briefly, this was a phase III trial in which patients were randomised on a 1:1 basis to receive 
cyclophosphamide methotrexate and fluorouracil (CMF) or Epirubicin in addition to CMF (E-CMF).  
Results of this trial were first published in 2006.  Additional details are provided in the Supplementary 
Methods and in Supplementary Tables 1 and 2.    
Immunohistochemistry and scoring  
Immunohistochemistry (IHC) was conducted for CD8 and FOXP3 proteins at host institutions. Details 
of scoring systems and cut-points for positivity are provided in Supplementary Table 3.  Tissue 
microarrays (TMAs) were used to analyse large numbers of tumour samples simultaneously, each 
represented by a single 0.6mm tissue core.    Additional details of IHC scoring are provided in 
Supplementary Methods.  Absolute numbers of immunoreactive tumour infiltrating lymphocytes were 
counted and classified as ‘intratumoral’ (iT) if seen in direct contact with tumour cells and ‘stromal’ 
(S) if they were not in direct contact with tumour cells.  Tumours were classified into different 
molecular subtypes as previously described[16] (Supplementary Table 4).  T-cell counts were 
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dichotomised for statistical analyses using a pre-specified cut-point of zero versus any more than zero 
immunoreactive lymphocytes.  This cut-point was chosen because discrimination between tissue 
completely devoid of positive lymphocytes and tissue containing any positive lymphocytes is likely to 
be reliable.  Information on FOXP3+ T-lymphocytes was available for the SEARCH, NBCS and 
NEAT studies only. 
Statistical analyses 
Cox-regression models stratified by study were used to test for associations with breast cancer 
specific survival (BCSS).  Follow-up time was truncated at 10 years.  Women with ER-positive and 
ER-negative breast cancer were analysed separately because of differences in their patterns of short 
and long term survival[16].  Late entry for the SEARCH study was accounted for by left-truncation of 
survival time data.    Variables which showed a time-dependent association with survival, and 
therefore violated the Cox proportional-hazards assumption, were modelled by using an extended 
Cox-model to include a coefficient (T) which varied linearly as a function of the logarithm of time.  
Variables significantly associated with BCSS on univariate analysis were also evaluated in 
multivariate analysis.  Data on hormone therapy was not available for the NEAT study, hence 
multivariate models excluding this study and including hormone therapy as a covariate are presented 
in the supplementary material.  Cochran’s Q-test was used to test for heterogeneity of the prognostic 
effect of T-cell status according to different patient and tumour subgroups and of differential benefit 
of anthracyclines according to T-cell status in the NEAT trial.  To determine whether cytotoxic and 
regulatory T-lymphocytes contributed complementary prognostic value and therefore whether their 
prognostic accuracy could be improved by accounting for it, an interaction term between the variables 
was included in exploratory Cox-regression analyses.  Multiple imputation was used to adjust for the 
bias of missing data; this is a statistical technique which resolves missing values by predicting their 
probable value based on the complete data using a multivariate regression model. The variability 
between imputed (predicted) values is accounted for by producing multiple datasets.  We imputed 
fifty datasets including all 12,439 patients; survival estimates based on these data were computed per 
dataset and combined to account for between and within-dataset variation (additional details are 
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provided in Supplementary Methods).  The distributions of imputed versus observed values for all 
variables included in the model are illustrated in Supplementary Figure 1.  The necessity of adjusting 
for missing data is illustrated by Supplementary Figure 2 which depicts significant differences in 
survival in subgroups of patients according to whether data was missing for CD8, FOXP3, ER and 
HER2.  Relative survival estimates derived from imputed data are presented in the main report and 
estimates from the complete case analysis detailed in the supplementary material.  Absolute survival 
estimates are based on complete data.  Statistical methods are further detailed in the supplementary 
material.  Analyses are reported in accordance with REMARK guidelines[17].  All analyses were 
conducted using Intercooled Stata version 11.2 (Stata Corp, College Station, TX, USA).  Data 
analysis was conducted by H R Ali; the Stata code used for all survival analyses can be made 
available upon request from the corresponding author.        
Results 
Details of the participating studies and patient characteristics are provided in Supplementary Tables 1-
2 and Supplementary Figure 3.  In total, there were 12,439 patients of which 2,674 (21%) died of 
breast cancer within 10 years of diagnosis.  The median survival was 9.57 years (range 0.05 – 20.6 
years).  Supplementary Figure 4 illustrates the distribution of lymphocyte counts by study, tumour 
morphology and molecular subtype. 
Prognostic value of T-cells 
In ER-negative tumours the presence of stromal and intratumoral CD8+ lymphocytes were 
independently associated with a reduced relative risk of death from breast cancer (Table 1 and Figure 
1).  Supplementary Tables 5 and 6 detail univariate Cox-regression analyses for all variables.  Table 1 
contains the multivariate Cox-regression models (Supplementary Tables 7-9 detail multivariate 
models based on complete data and including hormone therapy as a covariate).  The adjusted hazard 
ratio (HR) for iT-CD8+ positivity was 0.72 (95% confidence interval (95% CI), 0.62-0.84, 
P=0.00003) and for S-CD8+ the HR was 0.79 (95% CI, 0.67-0.93, P=0.004).    For women with ER-
negative breast cancer, absolute survival estimates (Kaplan-Meier survival function) for tumours 
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positive for both iT-CD8+ and S-CD8+ lymphocytes compared to tumours negative for both were 77% 
(95% CI, 74%-79%) versus 66% (95% CI, 62%-70%) at five years and 71% (95% CI, 68%-74%) 
versus 58% (95% CI, 54%-63%) at ten years (Figure 1).    The presence of CD8+ lymphocytes was not 
associated with BCSS in ER-positive breast tumours (Supplementary Table 5). The presence of 
FOXP3+ lymphocytes was not associated with BCSS after adjustment for known prognostic factors 
(Supplementary Tables 10 and 11) irrespective of ER-status.  Unadjusted Cox-regression analyses 
including an interaction term between cytotoxic and regulatory T-cell variables did not reveal a 
significant interaction between intratumoral or stromal T-cell types irrespective of ER-status 
(Supplementary Table 12). 
Subgroup analysis and chemotherapy 
Significant heterogeneity of the prognostic effect of T-cells was observed for different patient and 
tumour subgroups.  Figure 2 shows HRs and 95% CIs from univariate Cox-regression analyses of iT-
CD8+ lymphocytes as separate forest plots for ER-positive and ER-negative disease; equivalent plots 
for S-CD8+, iT-FOXP3+ and S-FOXP3+ status are presented as Supplementary Figures 5-11.   In 
particular, the prognostic effect of iT-CD8+ lymphocytes differed by human epidermal growth factor 
receptor 2 (HER2) status in ER-positive breast cancer (Pheterogeneity=0.006).  For ER-positive HER2-
negative tumours the HR was 1.16 (95% CI, 1.02-1.32) and for ER-positive HER2-positive tumours 
the HR was 0.76 (95% CI, 0.58-1.00).  Following adjustment for histological grade, the HR associated 
with iT-CD8+ status in ER-positive HER2-negative tumours was 1.04 (95% CI, 0.91-1.20).  Figure 3 
shows the absolute differences in survival of iT-CD8+ status within luminal and non-luminal breast 
tumours.  Based on this finding, multivariate analysis of iT-CD8+ lymphocytes was conducted within 
the ER-positive HER2-positive subgroup as detailed in Table 2 and Supplementary Table 13.  The HR 
for iT-CD8+ lymphocytes was 0.73 (95% CI, 0.56-0.96, P=0.022) after adjustment for known 
prognostic factors.   
Supplementary Figures 12 and 13 depict the HRs and 95% CIs from Cox-regression models adjusted 
for tumour size, positive lymph nodes and grade according to whether adjuvant chemotherapy was 
received for different T-cell types.  There was no significant heterogeneity of the prognostic effect of 
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T-cells according to whether chemotherapy was administered.  In order to account for differences in 
chemotherapeutic regimens between studies, subgroup analyses by study were conducted for iT-CD8+ 
status (Supplementary Figure 14); no significant difference in prognostic effect was observed by 
whether chemotherapy had been received within each study.  Supplementary Figures 15 and 16 are 
forest plots of the adjusted HRs and 95% CIs for the benefit of the addition of epirubicin to 
cylcophosphomide, methotrexate and fluorouracil (CMF) in the NEAT trial in patient subgroups 
defined by T-cell status.  Although there was no evidence of significant differential benefit of 
epirubicin in these T-cell defined subgroups, there was a trend toward increased benefit in ER-
positive patients with tumours devoid of stromal cytotoxic T-cells (Pheterogeneity =0.087) and, in ER-
negative patients, with tumours positive for iT-CD8+ lymphocytes (Pheterogeneity=0.12) using imputed 
data.  Analysis restricted to cases with complete data only showed that the presence of iT-CD8+ cells 
was significantly associated with increased relative benefit from epirubicin (HR = 0.60, 95% CI, 0.37 
- 0.96) compared to cases negative for iT-CD8+ cells (HR = 1.47, 95% CI, 0.72 - 3.02; 
Pheterogeneity=0.039).   
Further subgroup analyses were conducted to determine whether the prognostic effect of T-cells 
varied according to tumour cell proliferation as suggested by a recent study[18] and according to 
patient age as a result of the age-related decline of the immune system known as immunosenescence 
[19].  The results of these analyses are depicted in Supplementary Figure 17.  No significant 
heterogeneity was observed by tumour proliferation status or age at diagnosis. 
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Discussion 
This study of 12,439 women with breast cancer is the largest evaluation of T-cells as a tumour marker 
in breast cancer to date.  It shows that the presence of CD8+ T-cells in ER-negative breast tumours is 
associated with a reduction in the relative hazard of dying from breast cancer of between 57% and 
21% depending on their location (intratumoral, stromal or both) and, for intratumoral CD8+ T-cells, 
with a 27% reduction in the hazard of dying from breast cancer in ER-positive HER2-positive 
tumours.     
We included a large number of well-characterised patients in this study and therefore our conclusions 
are statistically robust.  In addition we have been able to evaluate breast cancer as a group of related 
diseases (molecular subtypes) rather than a single entity.  We have also adjusted our estimates for the 
bias of missing data for any of the variables included in multivariate analyses by using multiple 
imputation[20].  Supplementary Figure 2 depicts survival plots of subgroups of patients according to 
whether data was missing for CD8, FOXP3, ER and HER2.  Missing data was significantly associated 
with improved survival; this is because data was not missing completely at random but was correlated 
with other variables such as tumour size.  For example, it is more likely that there will be insufficient 
tissue for analysis in smaller tumours compared to larger tumours.  This means that cases with 
complete data are a biased representation of the overall population.  However, unbiased estimates can 
be computed by using a method to resolve missing values such as multiple imputation[21, 22].  This 
explains why the distribution of imputed data generally favoured smaller, lower grade, ER-positive 
tumours for which data is more likely to be missing (Supplementary Figure 1).  The sampling error 
associated with representation of tumours in TMAs can result in reduced power to detect associations.  
However, only by using TMAs has it been feasible to conduct a study of this size and this has 
proportionally reduced the likelihood of false-negative findings.  Although slight between-institution 
variation in methods of lymphocyte detection may have introduced some bias, the diversity of studies 
included in this analysis has also meant that our conclusions are likely to reflect the complete 
heterogeneity of breast cancer and will therefore be applicable to other populations.   
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Since the immune response can exert paradoxical effects in cancer, we evaluated two functionally 
distinct subsets of T-cells: cytotoxic and regulatory T-cells.  Cytotoxic T-cells, identifiable by CD8 
expression, form a major effector component of the adaptive immune system.  Cells which present 
foreign antigens in association with the major histocompatibility complex (MHC) class I molecule are 
recognised by cytotoxic T-lymphocytes through a specific interaction between the presented antigen 
and the T-cell receptor (TCR)[23].  This interaction causes the activated T-cell to release proteins 
such as perforin and granzyme which kill the cell through membranolysis[23].  These mechanisms 
can act on tumour cells which, unlike normal cells, can present atypical antigens[24, 25].  Regulatory 
T-cells, which express FOXP3, act to diminish an immune response to self-antigens. The hypothesis 
that regulatory T-cells may be recruited by tumours to evade immune destruction is supported by the 
observation that their ablation in mice enables an effective anti-tumour immune response[9].  
Previous studies evaluating the prognostic value of FOXP3+ T-cells have reported conflicting 
findings[10, 11, 26].   
There have been several studies in breast cancer which find that some readout of the immune response 
is predictive of chemosensitivity[12, 13, 27].    In the NEAT trial a differential relative benefit of E-
CMF over CMF was not observed between patients with tumours positive for T-cells and those with 
tumours negative for T-cells based on analysis of imputed data (Supplementary Figures 15), however 
analysis of cases with complete data showed a significant interaction between the relative benefit of 
epirubicin and iT-CD8+ status in ER-negative tumours (Supplementary Figure 16).  Based on these 
findings it is possible that the efficacy of particular chemotherapies e.g. anthracyclines may be 
enhanced by cytotoxic T-cells.  It has been reported that infiltrating lymphocytes are predictive of 
response to trastuzumab in HER2-positive breast cancer, but this finding was based on a small sample 
size and, unlike in our much larger study, no overall association between infiltrating lymphocytes  and 
prognosis in HER2 positive disease was found[28].     
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This large multi-centre study demonstrates the importance of lymphocytic infiltration in ER-negative 
(both HER2-positive and HER2-negative) and ER-positive/HER2-positive breast cancer.  
Intratumoral and stromal CD8+ lymphocytes were independently associated with a reduced risk of 
death from breast cancer.  In conjunction with clinical parameters, assessment of the immune 
response may aid risk stratification of patients with these breast cancer subtypes.    
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Tables 
Table 1  
Multivariate Cox-regression analysis for breast cancer-specific survival based on multiple imputation 
for ER-positive and ER-negative breast cancer 
 
Table 2  
Multivariate Cox-regression analysis for breast cancer-specific survival based on multiple imputation 
for ER-positive HER2-positive breast cancer 
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Figure legends 
Figure 1 
Kaplan-Meier survival plot of patient groups defined by the presence of iT-CD8+ and S-CD8+ cells in 
ER-negative disease.  Unadjusted survival estimates at five and ten years for double-positive and 
double-negative tumours are shown.  Note numbers at risk account for delayed entry of patients 
enrolled in the SEARCH study. 
Figure 2 
Subgroup analyses by patient and tumour characteristics of the prognostic effect of iT-CD8+ cells in 
ER-positive (left) and ER-negative (right) breast cancer.  Definitions of molecular subtypes within 
ER-positive breast cancer (Lunminal 1a, Luminal 1b, Luminal 2) and ER-negative breast cancer 
(HER2, CBP = core-basal-phenotype, 5NP = five-marker-negative phenotype) are defined in 
Supplementary Table 4. 
Figure 3 
Kaplan-Meier survival plots of patient groups defined by the presence of iT-CD8+ cells in luminal 
(left) and non-luminal (right) tumours.  Note numbers at risk account for delayed entry of patients 
enrolled in the SEARCH study.  Definitions of molecular subtypes within ER-positive breast cancer 
(Lunminal 1a, Luminal 1b, Luminal 2) and ER-negative breast cancer (HER2, CBP = core-basal-
phenotype, 5NP = five-marker-negative phenotype) are defined in Supplementary Table 4.   
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Supporting Information 
Supplementary Tables 
Supplementary Table 1 
Summary of participating studies. 
Supplementary Table 2 
Patient and tumour characteristics of cases included in the analysis. 
Supplementary Table 3 
Protocols and reagents for immunohistochemistry by study. 
Supplementary Table 4 
Scheme used molecular subtyping of tumours. 
Supplementary Table 5 
Univariate Cox-regression analyses for BCSS based on multiple imputation. 
Supplementary Table 6 
Univariate Cox-regression analyses for BCSS based on the complete case analysis. 
Supplementary Table 7 
Multivariate Cox-regression analysis for BCSS based on the complete case analysis in ER-positive 
and ER-negative breast cancer including CD8+ T-cells. 
Supplementary Table 8 
Multivariate Cox-regression analysis for BCSS based on multiple imputation and including hormone 
therapy as a covariate. 
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Supplementary Table 9 
Multivariate Cox-regression analysis for BCSS based on the complete case analysis and including 
hormone therapy as a covariate. 
Supplementary Table 10 
Multivariate Cox-regression analysis for BCSS based on multiple imputation including iT-FOXP3+ in 
ER-positive breast cancer. 
Supplementary Table 11 
Multivariate Cox-regression analysis for BCSS based on the complete case analysis including iT-
FOXP3+ in ER-positive breast cancer. 
Supplementary Table 12 
Cox-regression analyses for BCSS based on multiple imputation including an interaction term for all 
combinations of intratumoral or stromal cytotoxic and regulatory T-cells in ER-positive and ER-
negative breast cancer. 
Supplementary Table 13 
Multivariate Cox-regression analysis based on the complete case analysis of iT-CD8+ cells in ER-
positive HER2-positive breast cancer. 
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Supplementary Figures  
Supplementary Figure 1 
Histograms illustrating the relative distributions of observed values and imputed values by variables 
included in the imputation model. 
Supplementary Figure 2 
Kaplan-Meier survival plots of subgroups of patients defined by whether data was missing for CD8, 
FOXP3, ER and HER2. 
Supplementary Figure 3 
Spine plots illustrating the percentage distributions of clinical and molecular characteristics by study.   
Supplementary Figure 4 
Distribution of T-cell counts by study, histological type and molecular subtype illustrated as box-
plots.  Note T-cell counts for the BCCA study were capped at an upper limit of 100. 
Supplementary Figure 5 
Forest plots illustrating the univariate HR and 95% CI for association between iT-CD8+ status and 
survival in different subgroups.  Estimates are based on the complete case analysis (CCA). 
Supplementary Figure 6 
Forest plots illustrating the univariate HR and 95% CI for association between S-CD8+ status and 
survival in different subgroups.  Estimates are based on imputed data. 
Supplementary Figure 7 
Forest plots illustrating the univariate HR and 95% CI for association between S-CD8+ status and 
survival in different subgroups.  Estimates are based on the complete case analysis (CCA). 
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Supplementary Figure 8 
Forest plots illustrating the univariate HR and 95% CI for association between iT-FOXP3+ status and 
survival in different subgroups.  Estimates are based on imputed data. 
Supplementary Figure 9 
Forest plots illustrating the univariate HR and 95% CI for association between iT-FOXP3+ cell status 
and survival in different subgroups.  Estimates are based on the complete case analysis. 
Supplementary Figure 10 
Forest plots illustrating the univariate HR and 95% CI for association between S-FOXP3+ status and 
survival in different subgroups.  Estimates are based on imputed data. 
Supplementary Figure 11 
Forest plots illustrating the univariate HR and 95% CI for association between S-FOXP3+ cell status 
and survival in different subgroups.  Estimates are based on the complete case analysis. 
Supplementary Figure 12 
Forest plot illustrating the prognostic effect of CD8+ and FOXP3+ lymphocytes in ER-negative breast 
cancer according to whether adjuvant chemotherapy was administered.  HRs and 95%CIs are based 
on imputed analyses and are adjusted for tumour size, grade and number of positive lymph nodes. 
Supplementary Figure 13 
Forest plot illustrating the prognostic effect of CD8+ and FOXP3+ lymphocytes in ER-negative breast 
cancer according to whether adjuvant chemotherapy was administered.  HRs and 95%CIs are based 
on the complete case analysis and are adjusted for tumour size, grade and number of positive lymph 
nodes. 
Supplementary Figure 14 
Forest plot illustrating the prognostic effect of iT-CD8+ lymphocytes in ER-negative and ER-positive 
breast cancer according to whether adjuvant chemotherapy was administered separately for the three 
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observational studies (SEARCH, NBCS, BCCA).  HRs and 95%CIs are adjusted for tumour size, 
grade and number of positive lymph nodes (MI = multiple imputation, CCA = complete case 
analysis). 
Supplementary Figure 15 
Forest plot illustrating the treatment effect of E-CMF versus CMF by subgroups defined by the 
presence of CD8+ and FOXP3+ lymphocytes in ER-positive and ER-negative disease.  HRs and 
95%CIs are based on imputed data and are adjusted for tumour size, grade and number of positive 
lymph nodes. 
Supplementary Figure 16 
Forest plot illustrating the treatment effect of E-CMF versus CMF by subgroups defined by the 
presence of CD8+ and FOXP3+ lymphocytes in ER-positive and ER-negative disease.  HRs and 
95%CIs are based on the complete case analysis (CCA) and are adjusted for tumour size, grade and 
number of positive lymph nodes. 
Supplementary Figure 17 
Trends in hazard ratios and 95% confidence intervals for T-cell status according to tumour 
proliferation and diagnosis age.  Estimates are adjusted for tumour size, histological grade and 
positive axillary lymph nodes.  Analyses are based on imputed data.  Estimates and confidence 
intervals associated with iT-CD8+ cells are represented as dark blue, those with S-CD8+ as light blue, 
those with iT-FOXP3+ as dark red and those with S-FOXP3+ as light red.  Box sizes are proportional 
to the number of subjects in each subgroup.   
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Table 1: Multivariate Cox-regression analysis for breast cancer-specific survival 
based on multiple imputation for ER-positive and ER-negative breast cancer 
ER-positive 
Variable Categories Subjects† HR 95% CI P T‡ 95% CI P  
Age ≤55 years, >55 years  
8775 
1.89 1.42 2.50 0.00001 0.77 0.64 0.91 0.0031 
Positive lymph nodes 0, 1, 2-4, 5-9, ≥10 1.56 1.41 1.74 <0.00001 0.94 0.88 1.0 0.06 
Tumour size 
<10mm, 10-19mm, 20-29mm, 
30-49mm, ≥50mm 
1.32 1.24 1.40 <0.00001 
    
Grade 1, 2, 3 2.53 1.93 3.31 <0.00001 0.76 0.64 0.90 0.001 
Chemotherapy No, Yes 1.62 1.41 1.86 <0.00001 
    
PR status Negative, Positive 0.32 0.24 0.44 <0.00001 1.57 1.30 1.91 <0.00001 
HER2 status Negative, Positive 1.50 1.29 1.74 <0.00001 
    
iT-CD8 Negative, Positive 0.95 0.85 1.07 0.43 
    
ER-negative 
Positive lymph nodes 0, 1, 2-4, 5-9, ≥10 
3591 
1.43 1.36 1.51 <0.00001 
    
Tumour size 
<10mm, 10-19mm, 20-29mm, 
30-49mm, ≥50mm 
1.23 1.15 1.32 <0.00001 
    
Grade 1, 2, 3 2.05 1.48 2.83 0.00002 0.72 0.57 0.91 0.007 
Chemotherapy No, Yes 1.40 1.19 1.64 0.00003 
    
PR status Negative, Positive 0.31 0.18 0.51 0.00001 1.93 1.33 2.81 0.0006 
HER2 status Negative, Positive 1.29 1.13 1.49 0.0002 
    
iT-CD8 Negative, Positive 0.72 0.62 0.84 0.00003 
    
S-CD8 Negative, Positive 0.79 0.67 0.93 0.004         
†Sample size varied between imputed datasets.  Reported sizes are the smallest of fifty imputations. 
‡ Variables which violated the proportional hazards assumption were accounted for by an extended Cox-model where the beta-coefficient 
varies linearly with the natural logarithm of time.  ‘T’ represents the exponent of the extended coefficient where a value >1 implies 
increasing hazard over time whereas a value of <1 implies decreasing hazard over time. 
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Table 2: Multivariate Cox-regression analysis for breast cancer-specific survival 
based on multiple imputation for ER-positive HER2-positive breast cancer 
ER-POSITIVE HER2-POSITIVE 
Variable Categories Subjects† HR 95% CI P T‡ 95% CI P  
Positive lymph nodes 0, 1, 2-4, 5-9, ≥10 
772 
1.40 1.27 1.54 <0.00001 
    
Tumour size 
<10mm, 10-19mm, 20-29mm, 
30-49mm, ≥50mm 
1.33 1.16 1.52 0.00004 
    
Grade 1, 2, 3 2.73 1.26 5.92 0.01 0.56 0.33 0.95 0.03 
PR status Negative, Positive 0.35 0.17 0.69 0.002 1.73 1.04 2.90 0.04 
iT-CD8 Negative, Positive 0.73 0.56 0.96 0.02         
†Sample size varied between imputed datasets.  Reported sizes are the smallest of fifty imputations. 
‡ Variables which violated the proportional hazards assumption were accounted for by an extended Cox-model where the beta-coefficient 
varies linearly with the natural logarithm of time.  ‘T’ represents the exponent of the extended coefficient where a value >1 implies 
increasing hazard over time whereas a value of <1 implies decreasing hazard over time. 
 
Figure 1 
Kaplan-Meier survival plots of patient groups defined by the presence of iT-CD8+ and S-CD8+ cells in 
ER-negative disease.  Unadjusted survival estimates at five and ten years for double-positive and 
double-negative tumours are shown.  Note numbers at risk account for delayed entry of patients 
enrolled in the SEARCH study.   
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Figure 2
Subgroup analyses of the prognostic effect of iT-CD8+ cells in ER-positive (left) and ER-negative (right) 
breast cancer.
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Figure 3 
Kaplan-Meier survival plots of patient groups defined by the presence of iT-CD8+ cells in luminal (left) and 
non-luminal (right) tumours.  Note numbers at risk account for delayed entry of patients enrolled in the 
SEARCH study. 
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Supplementary Methods 
Study populations 
Patients recruited to the Study of Epidemiology and Risk Factors in Cancer Heredity (SEARCH) 
study provided written informed consent; the study is approved by the Cambridgeshire 4 Research 
ethics committee (02/5/42).  SEARCH is a prospective population-based study of women diagnosed 
with breast cancer in East Anglia, England.  Cases are ascertained through the East Anglia Cancer 
Registry and comprise prevalent cases (women diagnosed under the age of 55 years during 1991-1996 
and who were still alive at study commencement in 1996) and incident cases (women under the age of 
70 years and diagnosed after 1996).  Patients were treated according to regional protocols. 
The British Columbia Cancer Agency (BCCA) study was approved by the Clinical Research Ethics 
Committee Board of the BCCA and the University of British Columbia; since this study utilised 
anonymised archival specimens, the need for informed consent was waived in accordance with the 
Canadian Tri-Council Policy Statement for ethical research involving human subjects.  This study 
comprised women diagnosed with breast cancer between 1986 and 1992 in British Columbia and 
referred to BCCA for consideration of adjuvant therapy.  Approximately 75% of women diagnosed 
with breast cancer in British Columbia were referred to BCCA during the study period; the remaining 
25% were those for whom adjuvant therapy was not indicated. 
The Nottingham Tenovus Primary Breast Cancer Series (NBCS) comprises patients diagnosed and 
treated at Nottingham City Hospital between 1987 and 1998 was approved by Nottingham Research 
Ethics Committee 2.   Data on survival time and locoregional recurrence were prospectively 
maintained.  Patients were treated uniformly according to institutional protocol.     
Details of the National Epirubicin Adjuvant Trial and BR9601 trial (here collectively referred to as 
NEAT) have been published previously[1].  Briefly, this was a phase III trial in which patients were 
randomised on a 1:1 basis to receive cyclophosphamide methotrexate and fluorouracil (CMF) or 
Epirubicin in addition to CMF (E-CMF); all participants provided written informed consent and the 
 
 
study was approved by local and central ethics review committees.  Patients were recruited to the 
NEAT trial by 111 clinicians at 65 centres in England between 1996 and 2001; 26 clinicians at 10 
centres in Scotland recruited patients to the BR9/601 trial.  Patients were eligible for these trials if 
they had completely excised early breast cancer, required adjuvant chemotherapy and could begin 
treatment within ten weeks of surgery.  Results of this trial were first published in 2006[2].  
Additional details are described in Supplementary Table 1.  Patient characteristics are detailed in 
Supplementary Table 2. 
Some patients were recruited to both the SEARCH and NEAT studies of which it was possible to 
identify approximately 60% (44 cases).  Although the remaining duplicate instances remain they are 
likely to be exceptionally rare (approximately 30 cases (0.2%)) in this large study, hence will not 
influence the validity of analyses.   
Immunohistochemistry and scoring 
Details of reagents and protocols for IHC by study are provided in Supplementary Table 3.  All 
tumours were represented by one 0.6 mm tissue core on tissue microarrays (TMAs) constructed at the 
respective host institutions.  ER status was assessed based on IHC applied to TMAs and scored using 
the Allred scoring system for the SEARCH and NEAT studies and the percentage of positive tumour 
cells for the NBCS and BCCA studies.  IHC and scoring were conducted at the host institutions.  The 
same reagents and protocols for IHC were used for staining of the SEARCH and NEAT studies; one 
pathologist (HRA) scored the samples from these studies for infiltrating lymphocytes.  Lymphocytes 
were manually quantified by counting the absolute number of positive lymphocytes according to their 
micro-anatomic location (intratumoral or stromal).  Tumour infiltrating lymphocytes were classified 
as ‘intratumoral’ (iT) if they were seen in direct contact with cancer cells and ‘stromal’ (S) if they 
were not in direct contact with cancer cells.  For the NBCS study the stromal category was generated 
by the addition of the ‘peri-tumoral’ (close to but not touching tumour cells) and ‘distant stroma’ 
categories previously reported[3].  In the BCCA study, the absolute numbers of CD8+ lymphocytes 
were counted up to a maximum of 100.  To make CD8+ lymphocyte counts comparable between all 
four studies, scores exceeding 100 were changed to 100.  T-cell counts were dichotomised for 
 
 
statistical analyses using a pre-specified cut-point of zero versus any more than zero immunoreactive 
lymphocytes.  This cut-point was chosen because discrimination between tissue completely devoid of 
positive lymphocytes and tissue containing any positive lymphocytes is likely to be reliable.  
Information on FOXP3+ T-cells was available for the SEARCH, NBCS and NEAT studies only. 
Statistical analyses 
The primary endpoint was breast cancer specific survival (BCSS). Follow-up time was truncated at 10 
years from the date of diagnosis.  Following removal of cases with missing follow-up time (NEAT 
study: 6 patients, NBCS: 61 patients) 12,439 cases remained.  Women with ER-positive and ER-
negative tumours were analysed separately because they have different patterns of short- and long-
term survival.  Cox proportional-hazards regression models were used to assess the association 
between T-cells and BCSS.  All regression models were stratified by study.  SEARCH is an on-going 
prospective study to which patients are recruited at different times after their initial diagnosis.  Late 
entry refers to the enrolment of patients into the ongoing SEARCH study at some point after the date 
of diagnosis.  This can be a potential source of bias in observational studies because to be enrolled 
into the study patients must survive the time between date of diagnosis and enrolment.  Since those 
who do not survive this period are never enrolled, late entry can lead to biased estimates for that time 
frame.  Survival time was left-truncated to adjust for this bias.  Left-truncation means that patients are 
only included in survival time analysis during their time under observation that is, following study 
enrolment.  For time-to-event analyses the date-of-diagnosis was used to define the start of follow-up 
time.  However, cases from the SEARCH study had their survival times left-truncated to study entry 
(time-under-observation).  This method produces unbiased estimates providing the proportional-
hazards assumption is not violated and study entry time is unrelated to outcome[4, 5].  The 
proportional hazards assumption was tested iteratively for all variables by using an extended 
regression model to include a coefficient which varies linearly as a function of the natural logarithm 
of time.  Variables were modelled as time-varying according to the significance of the p-value of the 
extended coefficient.  Variables which were best modelled as time-varying in univariate analyses 
were initially modelled as time-varying in multivariate analyses.  Variables significantly associated 
 
 
with outcome on univariate analysis were further assessed in multivariate analyses.  In addition to T-
cell counts, initial multivariate models included: age (≤55 years, >55 years), number of positive 
axillary lymph nodes (0, 1, 2-4, 5-9, ≥10)  tumour size (<10mm, 10-19mm, 20-29mm, 30-49mm, 
≥50mm), histological grade, PR status, HER2 status and whether chemotherapy was administered.  
Additional models including hormone therapy as a covariate but excluding the NEAT trial for which 
this data was not available, were also constructed.  Tumour size, lymph nodes and grade were 
modelled as continuous variables.  Multivariate models, including estimates for an interaction with 
time, were modified by backward elimination.   
Univariate Cox-regression analyses were also used to test for differences in the effect of T-cells on 
survival between patient subgroups.  Heterogeneity for the prognostic effect of T-cell status by study 
and patient subgroups was tested using Cochran’s Q-test.  The I2 statistic is also reported; this 
provides an estimate of the percentage of variation across subgroups that is due to heterogeneity rather 
than chance[6].  Using data from the NEAT trial, assessment of the ability of T-cell counts to predict 
differential benefit from the addition of Epirubicin to adjuvant chemotherapy was made by comparing 
estimates of treatment effect (E-CMF vs CMF) in subgroups defined by T-cell status using Cochran’s 
Q-test.  Interaction between CD8+ and FOXP3+ T-cells was investigated by including an interaction 
term in a Cox-regression model.  Absolute survival estimates adjusted for node status, tumour size 
and histological grade were made using the Kaplan-Meier method.   
Data were missing in varying proportions for different characteristics and studies (Supplementary 
Table 2).  Missingness can be correlated across variables particularly where some data points are 
dependent on biological samples so analyses based on the complete cases alone can be biased 
(Supplementary Figure 2).  To adjust for this bias we conducted multiple imputation by chained 
equations using the ice command in Stata[7].  This method produces multiple replicate datasets where 
missing values have been resolved under a model informed by the rest of the data.  All variables 
which were to be evaluated in multivariate analyses, histological type, Ki67, EGFR and CK56 status 
were included in the imputation model and fifty replicate datasets produced.  The logarithm of tumour 
size showed a near normal distribution hence was used in the imputation model and back-transformed 
 
 
subsequently.  Continuous T-cell counts were transformed into ordinal scores where a score of zero 
remained a separate category and successive categories were divided by every tenth count i.e. 0, 1-11, 
12-21, 22-31 etc.  All other variables were included as dichotomous, categorical or ordinal in 
imputation models.  Ordinal variables (grade, positive lymph nodes, T-cell counts, Ki67 expression) 
were imputed using ordered logistic regression.  The censoring indicator and the Nelson-Aalen 
cumulative hazard function were also included in the analysis as their inclusion has been shown to 
produce the least biased estimates[8, 9].  Estimates derived from regression analyses across fifty 
datasets were combined using Rubin’s rules which accounts for within-dataset and between-dataset 
variation.  Relative survival estimates derived from imputed data are presented in the main report and 
estimates from the complete case analysis detailed in the supplementary material.  Reported absolute 
survival estimates were made using complete data only.  The distributions of imputed values 
compared to observed values for all variables are illustrated as histograms in Supplementary Figure 1.  
All statistical analyses were compliant with REMARK guidelines[10] and were conducted using 
Intercooled Stata version 11.2 (Stata Corp, College Station, TX, USA).    
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Supplementary Table 1: Summary of participating studies 
Study 
(N) Type 
Deaths from 
breast cancer   
Median time at-
risk (years) Study design Chemotherapy 
SEARCH 
(4,079) Population-based 508 (12%) 7.9 
Cases ascertained through the East Anglia 
Cancer Registry.  There are (a) prevalent cases 
diagnosed under the age of 55 years during 1991-
1996 and still alive in 1996 and (b) incident cases 
under the age of 70 years and diagnosed after the 
age of 70 years. 
Variable between hospitals and over time 
BCCA† 
(4,520) Hospital-based 1252 (28%) 12.31 
Women diagnosed with invasive breast cancer 
during 1986-1992 and referred to the BCCA for 
consideration of adjuvant therapy.     
Variable regimens, including (i) 
Doxorubicin and cyclophosphamide, (ii) 
cyclophosphamide, methotrexate and 
fluorouracil, (iii) fluorouracil, 
doxorubicin, cyclophosphamide, (iv) 
cyclophosphamide, epirubicin, 
fluorouracil 
NBCS† 
(1,842) Hospital-based 429 (23%) 10.6 
Consecutive series of patients diagnosed between 
1987 and 1998 and enrolled in the Nottingham 
Tenovus Primary Breast Cancer series study. 
Cyclophosphamide, methotrexate, 
fluorouracil (CMF) 
NEAT‡ 
(1,998) Randomised controlled trial 485 (24%) 6.9 A UK-based phase III trial 
  Patients were randomised on a 1:1 basis 
to receive CMF alone or Epirubicin plus 
CMF (E-CMF).   
†For these studies analyses based on T-cell data have been published previously. 
‡Also includes patients enrolled in the BR9601 trial (NEAT, N=1,684 and BR9601, N=341). 
§Summary statistics reflect survival analyses where follow-up time was truncated at ten years. 
 
 
Supplementary Table 2: Patient and tumour characteristics of cases included in 
the analysis 
  Study 
Variable SEARCH   BCCA   NBCS   NEAT   Total 
 No. %  No. %  No. %  No. %  No. % Age                
≤55 years 2529 62  1755 39  963 52  1504 75  6751 54 >55 years 1550 38  2765 61  879 48  494 25  5688 46 Positive lymph nodes               0 2292 56  2539 56  1037 56  575 29  6443 52 1 569 14  614 14  288 16  341 17  1812 15 2 to 4 508 12  733 16  231 13  514 26  1986 16 5 to 9 184 5  343 8  58 3  211 11  796 6 10+ 120 3  182 4  14 1  80 4  396 3 Missing 406 10  109 2  214 12  277 14  1006 8 Tumour size               <10mm 444 11  0 0  147 8  82 4  673 5 10-19mm 1741 43  833 18  822 45  564 28  3960 32 20-29mm 1003 25  1632 36  642 35  687 34  3964 32 30-49mm 497 12  1486 33  213 12  464 23  2660 21 50+mm 145 4  472 10  17 1  159 8  793 6 Missing 249 6  97 2  1 0  42 2  389 3 Grade               1 799 20  231 5  344 19  117 6  1491 12 2 1701 42  1731 38  611 33  670 34  4713 38 3 1102 27  2303 51  887 48  1182 59  5474 44 Missing 477 12  255 6  0 0  29 1  761 6 Morphology               Ductal 3057 75  3555 79  1034 56  1617 81  9263 74 Lobular 594 15  308 7  131 7  182 9  1215 10 Medullary 45 1  70 2  45 2  25 1  185 1 other 375 9  587 13  597 32  142 7  1701 14 Missing 8 0  0 0  35 2  32 2  75 1 Endocrine therapy               
No 837 21  2712 60  1103 60  0
† 0  4652 37 
Yes 3231 79  1808 40  655 36  0 0  5694 46 Missing 11 0  0 0  84 5  1998 100  2093 17 Chemotherapy               
No 2472 61  2993 66  1460 79  2
‡ 0  6927 56 
Yes 1242 30  1527 34  303 16  1996 100  5068 41 Missing 365 9  0 0  79 4  0 0  444 4 ER status               Negative 757 19  1335 30  451 24  644 32  3187 26 Positive 2267 56  3064 68  1269 69  992 50  7592 61 Missing 1055 26  121 3  122 7  362 18  1660 13 PR status               Negative 874 21  1959 43  694 38  800 40  4327 35 Positive 2173 53  2011 44  1004 55  1002 50  6190 50 Missing 1032 25  550 12  144 8  196 10  1922 15 HER2 status               Negative 2533 62  3720 82  1550 84  1515 76  9318 75 Positive 345 8  558 12  236 13  391 20  1530 12 Missing 1201 29  242 5  56 3  92 5  1591 13 Molecular subtype               Luminal 1a 1618 40  2268 50  825 45  632 32  5343 43 Luminal 1b 214 5  138 3  183 10  83 4  618 5 Luminal 2 200 5  251 6  113 6  189 9  753 6 HER2 118 3  276 6  111 6  144 7  649 5 CBP 210 5  375 8  189 10  170 9  944 8 5NP 127 3  178 4  89 5  85 4  479 4 Missing 1592 39  1034 23  332 18  695 35  3653 29 iT-CD8 status               Negative 1138 28  2587 57  920 50  591 30  5236 42 Positive 1115 27  1216 27  367 20  1044 52  3742 30 Missing 1826 45  717 16  555 30  363 18  3461 28 S-CD8 status               Negative 468 11  1533 34  229 12  448 22  2678 22 Positive 1785 44  2270 50  1058 57  1187 59  6300 51 Missing 1826 45  717 16  555 30  363 18  3461 28 iT-FOXP3 status               Negative 1728 42  0 0  1038 56  837 42  3603 29 Positive 458 11  0 0  357 19  821 41  1636 13 Missing 1893 46  4520 100  447 24  340 17  7200 58 S-FOXP3 status               Negative 1117 27  0 0  364 20  581 29  2062 17 Positive 1069 26  0 0  1031 56  1077 54  3177 26 Missing 1893 46   4520 100   447 24   340 17   7200 58 
†Data on endocrine therapy was not available for the NEAT trial. 
‡A small proportion of patients randomised did not ultimately receive chemotherapy.    
 
 
 
 
 
Supplementary Table 3: Protocols and reagents for immunohistochemistry by 
study 
Study Marker Clone Clonality Source Dilution Antigen retrieval Scoring system Cut-off 
SE
A
R
C
H
 &
 N
E
A
T 
ER 6F11/2 Mouse monoclonal Novocastra 1 in 70 
Citrate buffer pH6, 30 
minutes Allred >2 
PR PgR636 Mouse monoclonal Dako 1 in 50 
Citrate buffer pH6, 30 
minutes Allred >2 
HER2 c-erbB-2 Rabbit monoclonal Dako 1 in 250 
Citrate buffer pH6, 40 
minutes HercepTest ≥ 2 
CK5/6 D5/16 B4 Mouse monoclonal Dako 1 in 50 
Tris-EDTA buffer pH9, 
30 minutes Binary estimate >10% 
EGFR 31G7 Mouse monoclonal Zymed 1 in 25 
Proteinase K digestion, 
10 minutes Allred ≥ 2 
Ki67 MIB-1 Mouse monoclonal Dako 1 in 200 
Tris-EDTA buffer pH9, 
30 minutes 
Allred proportion 
(SEARCH) and 
percentage  (NEAT) 
NA 
CD8 SP16 Rabbit monoclonal Thermo Fisher 1 in 100 
Tris-EDTA buffer pH9, 
20 minutes Absolute count  >0 
FOXP3 236A/E7 Mouse monoclonal AbCam 1 in 50 
Citrate buffer pH6, 20 
minutes Absolute count  >0 
N
B
C
S 
ER 1D5 Mouse monoclonal Dako 1 in 80 Microwave H-score >10% 
PR PgR636 Mouse monoclonal Dako 1 in 50 Microwave H-score >10% 
HER2 c-erbB-2 Rabbit monoclonal Dako 1 in 250 None H-score >10% 
CK5/6 D5/16134 Mouse monoclonal 
Boehringer 
Biochemica 1 in 100 Microwave H-score >10% 
EGFR EGFR.113 Mouse monoclonal Novocastra 1 in 10 Microwave H-score >10% 
Ki67 MIB-1 Mouse monoclonal Dako 1 in 100 
Citrate buffer pH6, 20 
minutes Percentage  NA 
CD8 1A5 Mouse monoclonal Vector laboratories 1 in 50 
Citrate buffer pH6, 20 
minutes Absolute count >0 
FOXP3 236A/E7 Mouse monoclonal Abcam 1 in 100 
Tris-EDTA buffer pH8, 
20 minutes Absolute count >0 
B
C
C
A
 
ER SP1 Rabbit monoclonal Lab Vision 1 in 250 
Citrate buffer pH6, 8 
minutes Percentage  >0% 
PR 1E2 Rabbit monoclonal Ventana 
Ready-to-
use Ventana CC1 protocol Percentage  >0% 
HER2 SP3 Rabbit monoclonal Lab Vision 1 in 100 
Tris-EDTA buffer pH9, 
30 minutes HercepTest ≥ 2
† 
CK5/6 D5/16B4 Mouse monoclonal Zymed 1 in 100 Ventana CC1 protocol Binary estimate Any cytoplasmic and/or 
membranous staining  
EGFR 2-18C9 Mouse monoclonal Dako (PharmDx kit) 
Ready-to-
use 
Proteinase K digestion, 
5 minutes Binary estimate 
Ki67 SP6 
Rabbit 
monoclonal 
Lab Vision 1 in 200 Ventana CC1 protocol 
Percentage  NA 
CD8 C8/144B Mouse monoclonal Dako 1 in 100 
Dako target retrieval 
solution High pH 9, 20 
minutes 
Absolute count up to a 
maximum of 100 >0 
Allred Scoring System:   Staining intensity score: 1 = weak, 2 = moderate, 3 = strong; Proportion score: 1 = <1%, 2 = 1-10%, 3 = 11-33%, 4 = 34-66%, 5 = 
>66%; Total score = intensity score + proportion score = 0-8  
HercepTest™ : 0 = No staining or weak staining in ≤ 10% of cells; 1 = Weak incomplete membranous staining in >10% of cells; 2 = Moderate circumferential 
membranous staining in > 10% of cells; 3 = Strong circumferential membranous staining in >10% of cells 
†Cases with a score of '2' were subjected to fluorescence in situ hybridisation (FISH) analysis for assessment of the number of copies of the HER2 gene relative 
to the centromere of chromosome 17  using the PathVysion DNA probe kit (Abbott Molecular, Inc., Chicago, IL, USA). 
 
 
 
Supplementary Table 4: Scheme for molecular subtyping of tumours 
Molecular subtype ER and/or PR HER2 CK56 and/or EGFR 
Luminal 1a Positive Negative Negative 
Luminal 1b Positive Negative Positive 
Luminal 2 Positive Positive NA 
HER2 Negative Positive NA 
CBP Negative Negative Positive 
5NP Negative Negative Negative 
Abbreviations:  CBP – core basal phenotype, CK56 – cytokeratin 56, ER – estrogen receptor, EGFR – 
epidermal growth factor receptor, HER2 – human epidermal growth factor receptor 2, PR – progesterone 
receptor, 5NP – five marker negative phenotype. 
 
 
 
Supplementary Table 5: Univariate Cox-regression analyses for BCSS based on 
multiple imputation 
ER-Positive 
Variable Categories Subjects† HR 95% CI P T‡ 95% CI P  
Age  ≤55 years, >55 years  8775 1.73 1.30 2.30 0.0006 0.70 0.59 0.84 0.0001 
Positive lymph nodes 0, 1, 2-4, 5-9, ≥10 8775 1.93 1.74 2.14 <0.00001 0.91 0.85 0.98 0.008 
Tumour size 
<10mm, 10-19mm, 20-
29mm, 30-49mm, 
≥50mm 8775 1.98 1.71 2.29 <0.00001 0.90 0.82 0.98 0.02 
Grade  1, 2, 3 8775 3.73 2.87 4.85 <0.00001 0.70 0.59 0.82 0.00001 
Hormone therapy No, Yes 7576 2.65 1.91 3.69 <0.00001 0.73 0.60 0.90 0.003 
Chemotherapy No, Yes 8775 2.75 2.46 3.08 <0.00001 
    PR status Negative, Positive 8775 0.22 0.17 0.30 <0.00001 1.83 1.51 2.21 <0.00001 
HER2 status Negative, Positive 8775 3.94 2.85 5.45 <0.00001 0.66 0.52 0.82 0.0002 
iT-CD8 Negative, Positive 8775 1.12 0.99 1.25 0.07 
    S-CD8 Negative, Positive 8775 0.99 0.87 1.11 0.82 
    iT-FOXP3 Negative, Positive 5635 1.30 1.09 1.56 0.004 
    S-FOXP3 Negative, Positive 5635 1.07 0.91 1.26 0.39 
    ER-Negative 
Variable 
 
Subjects HR 95% CI P T 95% CI P  
Age  ≤55 years, >55 years  3591 1.11 0.98 1.26 0.11 
    Positive lymph nodes 0, 1, 2-4, 5-9, ≥10 3591 1.57 1.50 1.65 <0.00001 
    
Tumour size 
<10mm, 10-19mm, 20-
29mm, 30-49mm, 
≥50mm 3591 1.70 1.51 1.91 <0.00001 0.87 0.79 0.96 0.006 
Grade  1, 2, 3 3591 2.61 1.90 3.58 <0.00001 0.65 0.52 0.82 0.0003 
Hormone therapy No, Yes 2800 1.28 1.11 1.49 0.00101 
    Chemotherapy No, Yes 3591 2.25 1.95 2.60 <0.00001 
    PR status Negative, Positive 3591 0.26 0.15 0.42 <0.00001 2.14 1.49 3.08 0.00005 
HER2 status Negative, Positive 3591 1.60 1.40 1.82 <0.00001 
    iT-CD8 Negative, Positive 3591 0.75 0.66 0.87 0.00009 
    S-CD8 Negative, Positive 3591 0.80 0.70 0.93 0.003 
    iT-FOXP3 Negative, Positive 2213 0.86 0.72 1.04 0.12 
    S-FOXP3 Negative, Positive 2213 0.94 0.77 1.14 0.53         
†Sample size varied between imputed datasets.  Reported sizes are the smallest of fifty imputations. 
 
 
‡ Variables which violated the proportional hazards assumption were accounted for by an extended Cox-model where the beta-coefficient 
varies linearly with the natural logarithm of time.  ‘T’ represents the exponentiated extended coefficient where a value >1 implies increasing 
hazard over time whereas a value of <1 implies decreasing hazard over time. 
 
 
Supplementary Table 6: Univariate Cox-regression analyses for BCSS based on 
the complete case analysis 
ER-positive 
Variable Categories Subjects Events 
 
HR 95% CI P 
 
T† 95% CI P 
Age ≤55 years, >55 years  7591 1412 
 
1.76 1.30 2.36 0.0002 
 
0.71 0.59 0.86 0.0004 
Positive lymph nodes 0, 1, 2-4, 5-9, ≥10 7030 1265 
 
1.96 1.76 2.19 <0.00001 
 
0.91 0.84 0.97 0.006 
Tumour size 
<10mm, 10-19mm, 20-29mm, 
30-49mm, ≥50mm 
7431 1384 
 
1.95 1.68 2.27 <0.00001 
 
0.91 0.82 1.00 0.04 
Grade  1, 2, 3 7146 1331 
 
3.62 2.75 4.76 <0.00001 
 
0.72 0.60 0.85 0.00010 
Hormone therapy No, Yes 6549 1194 
 
2.86 2.04 3.99 <0.00001 
 
0.71 0.57 0.87 0.0001 
Chemotherapy No, Yes 7348 1392 
 
2.63 2.34 2.96 <0.00001 
     
PR status Negative, Positive 7045 1319 
 
0.22 0.16 0.30 <0.00001 
 
1.84 1.51 2.23 <0.00001 
HER2 status Negative, Positive 7165 1356 
 
3.81 2.73 5.30 <0.00001 
 
0.67 0.53 0.84 0.0005 
iT-CD8 Negative, Positive 5956 1184 
 
1.17 1.03 1.32 0.01 
     
S-CD8 Negative, Positive 5956 1184 
 
1.03 0.91 1.17 0.62 
     
iT-FOXP3 Negative, Positive 3263 541 
 
1.33 1.10 1.62 0.004 
     
S-FOXP3 Negative, Positive 3263 541 
 
1.07 0.90 1.28 0.45 
     
ER-negative 
Variable Categories Subjects Events 
 
HR 95% CI P 
 
T 95% CI P 
Age ≤55 years, >55 years  3187 967 
 
1.13 0.99 1.29 0.06 
     
Positive lymph nodes 0, 1, 2-4, 5-9, ≥10 2967 873 
 
1.71 1.56 1.86 <0.00001 
 
0.93 0.86 1.00 0.05 
Tumour size 
<10mm, 10-19mm, 20-29mm, 
30-49mm, ≥50mm 
3087 941 
 
1.72 1.52 1.94 <0.00001 
 
0.87 0.78 0.96 0.004 
Grade  1, 2, 3 3034 934 
 
2.61 1.88 3.61 <0.00001 
 
0.65 0.51 0.83 0.0006 
Hormone therapy No, Yes 2505 772 
 
1.27 1.09 1.48 0.002 
     
Chemotherapy No, Yes 3080 942 
 
2.27 1.95 2.63 <0.00001 
     
PR status Negative, Positive 2877 888 
 
0.26 0.16 0.44 <0.00001 
 
2.16 1.50 3.12 0.00004 
HER2 status Negative, Positive 2948 911 
 
1.54 1.34 1.76 <0.00001 
     
iT-CD8 Negative, Positive 2402 757 
 
0.75 0.65 0.87 0.0001 
     
S-CD8 Negative, Positive 2402 757 
 
0.82 0.70 0.95 0.01 
     
iT-FOXP3 Negative, Positive 1391 357 
 
0.83 0.67 1.03 0.09 
     
S-FOXP3 Negative, Positive 1391 357   1.02 0.80 1.28 0.90           
† Variables which violated the proportional hazards assumption were accounted for by an extended Cox-model where the beta-coefficient 
varies linearly with the natural logarithm of time.  ‘T’ represents the exponentiated extended coefficient where a value >1 implies increasing 
hazard over time whereas a value of <1 implies decreasing hazard over time. 
 
 
 
Supplementary Table 7: Multivariate Cox-regression analysis for BCSS based on 
the complete case analysis in ER-positive and ER-negative breast cancer 
including CD8+ T-cells 
ER-positive 
Variable Categories Subjects Events HR 95% CI P T† 95% CI P  
Age (>55 years) ≤55 years, >55 years  
4801 927 
2.19 1.51 3.18 0.00004 0.74 0.59 0.94 0.01 
Positive lymph 
nodes 
0, 1, 2-4, 5-9, ≥10 1.53 1.34 1.74 <0.00001 0.92 0.85 1.00 0.06 
Tumour size 
<10mm, 10-19mm, 20-
29mm, 30-49mm, 
≥50mm 
1.32 1.22 1.42 <0.00001 
    
Grade 1, 2, 3 2.62 1.84 3.73 <0.00001 0.73 0.59 0.91 0.005 
Chemotherapy No, Yes 1.89 1.59 2.26 <0.00001 
    
PR status Negative, Positive 0.30 0.20 0.43 <0.00001 1.70 1.33 2.16 0.00002 
HER2 status Negative, Positive 1.54 1.29 1.84 <0.00001 
    
iT-CD8 Negative, Positive 1.07 0.93 1.23 0.35 
    
ER-negative 
Age (>55 years) ≤55 years, >55 years  
1953 614 
1.31 1.09 1.58 0.004 
    
Positive lymph 
nodes 
0, 1, 2-4, 5-9, ≥10 1.52 1.37 1.70 <0.00001 0.90 0.83 0.99 0.03 
Tumour size 
<10mm, 10-19mm, 20-
29mm, 30-49mm, 
≥50mm 
1.26 1.15 1.38 <0.00001 
    
Grade 1, 2, 3 1.56 1.27 1.93 0.00004 
    
Chemotherapy No, Yes 1.82 1.45 2.28 <0.00001 
    
PR status Negative, Positive 0.20 0.10 0.39 <0.00001 3.06 1.92 4.90 <0.00001 
HER2 status Negative, Positive 1.17 0.98 1.39 0.09 
    
iT-CD8 Negative, Positive 0.70 0.59 0.84 0.0001 
    
S-CD8 Negative, Positive 0.75 0.63 0.91 0.003         
† Variables which violated the proportional hazards assumption were accounted for by an extended Cox-model where the beta-coefficient 
varies linearly with the natural logarithm of time.  ‘T’ represents the exponentiated extended coefficient where a value >1 implies increasing 
hazard over time whereas a value of <1 implies decreasing hazard over time. 
 
 
 
Supplementary Table 8: Multivariate Cox-regression analysis for BCSS based on 
multiple imputation and including hormone therapy as a covariate  
ER-positive 
Variable Categories Subjects HR 95% CI P T 95% CI P  
Age (>55 years) ≤55 years, >55 years  
7576 
2.13 1.54 2.94 0.00001 0.75 0.61 0.91 0.003 
Positive lymph nodes 0, 1, 2-4, 5-9, ≥10 1.54 1.37 1.73 <0.00001 0.93 0.87 1.00 0.04 
Tumour size 
<10mm, 10-19mm, 20-29mm, 
30-49mm, ≥50mm 1.36 1.27 1.45 <0.00001 
    Grade 1, 2, 3 2.65 1.95 3.59 <0.00001 0.75 0.62 0.90 0.002 
Hormone therapy No, Yes 1.08 0.95 1.24 0.23 
    Chemotherapy No, Yes 1.74 1.50 2.01 <0.00001 
    PR status Negative, Positive 0.36 0.26 0.50 <0.00001 1.42 1.16 1.75 0.0007 
HER2 status Negative, Positive 1.50 1.27 1.78 <0.00001 
    iT-CD8 Negative, Positive 0.93 0.82 1.07 0.30 
    ER-negative 
Positive lymph nodes 0, 1, 2-4, 5-9, ≥10 
2800 
1.40 1.32 1.49 <0.00001 
    
Tumour size 
<10mm, 10-19mm, 20-29mm, 
30-49mm, ≥50mm 1.20 1.11 1.30 <0.00001 
    Grade 1, 2, 3 2.25 1.55 3.27 0.00002 0.72 0.55 0.94 0.02 
Hormone therapy No, Yes 1.24 1.06 1.45 0.008 
    Chemotherapy No, Yes 1.50 1.27 1.77 <0.00001 
    PR status Negative, Positive 0.28 0.15 0.51 0.00005 1.88 1.21 2.91 0.005 
HER2 status Negative, Positive 1.28 1.09 1.49 0.002 
    iT-CD8 Negative, Positive 0.72 0.60 0.85 0.0002 
    S-CD8 Negative, Positive 0.80 0.67 0.96 0.01         
†Sample size varied between imputed datasets.  Reported sizes are the smallest of fifty imputations. 
‡ Variables which violated the proportional hazards assumption were accounted for by an extended Cox-model where the beta-coefficient 
varies linearly with the natural logarithm of time.  ‘T’ represents the exponentiated extended coefficient where a value >1 implies increasing 
hazard over time whereas a value of <1 implies decreasing hazard over time. 
 
 
Supplementary Table 9: Multivariate Cox-regression analysis for BCSS based on 
the complete case analysis and including hormone therapy as a covariate  
ER-positive 
Variable Categories Subjects Events HR 95% CI P T 95% CI P  
Age  ≤55 years, >55 years  
4170 809 
2.28 1.50 3.46 0.0001 0.76 0.59 0.98 0.03 
Positive lymph nodes 0, 1, 2-4, 5-9, ≥10 1.55 1.34 1.79 <0.00001 0.90 0.83 0.99 0.03 
Tumour size 
<10mm, 10-19mm, 20-29mm, 
30-49mm, ≥50mm 
1.36 1.25 1.48 <0.00001 
    
Grade 1, 2, 3 2.71 1.83 4.02 <0.00001 0.72 0.57 0.91 0.006 
Hormone Therapy No, Yes 1.00 0.84 1.18 0.96 
    
Chemotherapy No, Yes 1.99 1.66 2.39 <0.00001 
    
PR status Negative, Positive 0.32 0.21 0.48 <0.00001 1.56 1.21 2.02 0.0007 
HER2 status Negative, Positive 1.55 1.28 1.88 0.00001 
    
iT-CD8 Negative, Positive 1.03 0.88 1.19 0.74 
    
ER-negative 
Age  ≤55 years, >55 years  
1510 509 
1.37 1.11 1.68 0.003 
    
Positive lymph nodes 0, 1, 2-4, 5-9, ≥10 1.52 1.35 1.71 <0.00001 0.88 0.80 0.98 0.02 
Tumour size 
<10mm, 10-19mm, 20-29mm, 
30-49mm, ≥50mm 
1.19 1.08 1.32 0.0008 
    
Grade 1, 2, 3 1.75 1.39 2.22 <0.00001 
    
Hormone Therapy No, Yes 1.23 1.00 1.51 0.05 
    
Chemotherapy No, Yes 2.01 1.58 2.54 <0.00001 
    
PR status Negative, Positive 0.12 0.05 0.28 <0.00001 3.89 2.17 7.00 0.00001 
HER2 status Negative, Positive 1.21 1.00 1.46 0.06 
    
iT-CD8 Negative, Positive 0.67 0.55 0.81 0.00006 
    
S-CD8 Negative, Positive 0.78 0.64 0.96 0.02         
† Variables which violated the proportional hazards assumption were accounted for by an extended Cox-model where the beta-coefficient 
varies linearly with the natural logarithm of time.  ‘T’ represents the exponentiated extended coefficient where a value >1 implies increasing 
hazard over time whereas a value of <1 implies decreasing hazard over time. 
 
 
Supplementary Table 10: Multivariate Cox-regression analysis for BCSS based 
on multiple imputation including iT-FOXP3+ in ER-positive breast cancer 
ER-POSITIVE 
Variable Categories Subjects† HR 95% CI P T‡ 95% CI P  
Age ≤55 years, >55 years  
5635 
1.85 1.22 2.81 0.004 0.66 0.51 0.86 0.002 
Positive lymph nodes 0, 1, 2-4, 5-9, ≥10 1.61 1.37 1.90 <0.00001 0.99 0.89 1.10 0.79 
Tumour size 
<10mm, 10-19mm, 20-29mm, 30-
49mm, ≥50mm 
1.27 1.17 1.37 <0.00001 
    
Grade 1, 2, 3 2.62 1.80 3.82 <0.00001 0.79 0.63 0.99 0.04 
Chemotherapy No, Yes 1.02 0.83 1.27 0.82 
    
PR status Negative, Positive 0.34 0.22 0.53 <0.00001 1.56 1.15 2.11 0.004 
HER2 status Negative, Positive 2.82 1.73 4.60 0.00003 0.64 0.45 0.90 0.001 
iT-CD8 Negative, Positive 0.91 0.76 1.08 0.27 
    
iT-FOXP3 Negative, Positive 1.05 0.87 1.26 0.64         
†Sample size varied between imputed datasets.  Reported sizes are the smallest of fifty imputations. 
‡ Variables which violated the proportional hazards assumption were accounted for by an extended Cox-model where the beta-coefficient 
varies linearly with the natural logarithm of time.  ‘T’ represents the exponentiated extended coefficient where a value >1 implies increasing 
hazard over time whereas a value of <1 implies decreasing hazard over time. 
 
 
 
Supplementary Table 11: Multivariate Cox-regression analysis for BCSS based 
on the complete case analysis including iT-FOXP3+ in ER-positive breast cancer 
ER-POSITIVE 
Variable Categroies Subjects Events HR 95% CI P T 95% CI P  
Age (>55 years) ≤55 years, >55 years  
2295 371 
1.99 1.10 3.59 0.02 0.67 0.46 0.98 0.04 
Positive lymph nodes 0, 1, 2-4, 5-9, ≥10 1.47 1.18 1.85 0.0008 1.06 0.91 1.22 0.4 
Tumour size 
<10mm, 10-19mm, 20-
29mm, 30-49mm, ≥50mm 
1.24 1.11 1.39 0.0002 
    
Grade 1, 2, 3 2.32 1.38 3.91 0.001 0.86 0.62 1.18 0.3 
Chemotherapy No, Yes 0.98 0.72 1.34 0.90 
    
PR status Negative, Positive 0.24 0.13 0.46 0.00001 2.03 1.32 3.12 0.001 
HER2 status Negative, Positive 1.63 1.26 2.12 0.0003 
    
iT-CD8 Negative, Positive 1.06 0.85 1.33 0.58 
    
iT-FOXP3 Negative, Positive 1.09 0.86 1.38 0.47         
† Variables which violated the proportional hazards assumption were accounted for by an extended Cox-model where the beta-coefficient 
varies linearly with the natural logarithm of time.  ‘T’ represents the exponentiated extended coefficient where a value >1 implies increasing 
hazard over time whereas a value of <1 implies decreasing hazard over time.
 
 
Supplementary Table 12: Cox-regression analyses for BCSS based on multiple 
imputation including an interaction term for all combinations of intratumoral or 
stromal cytotoxic and regulatory T-cells  
Variable HR 95% CI P 
ER-POSITIVE 
iT-CD8+ 1.01 0.82 1.25 0.91 
iT-FOXP3+ 1.56 1.16 2.10 0.004 
Interaction (iT-CD8*iT-FOXP3) 0.94 0.63 1.39 0.75 
     
iT-CD8+ 1.12 0.84 1.50 0.44 
S-FOXP3+ 1.24 0.99 1.55 0.06 
Interaction (iT-CD8*S-FOXP3) 0.92 0.64 1.33 0.67 
     
S-CD8+ 0.87 0.69 1.09 0.23 
iT-FOXP3+ 1.46 0.98 2.16 0.06 
Interaction (S-CD8*iT-FOXP3) 1.05 0.66 1.65 0.84 
     
S-CD8+ 0.77 0.59 1.00 0.05 
S-FOXP3+ 1.10 0.78 1.56 0.59 
Interaction (S-CD8*S-FOXP3) 1.21 0.81 1.81 0.35 
ER-NEGATIVE 
iT-CD8+ 0.83 0.62 1.12 0.24 
iT-FOXP3+ 1.11 0.81 1.54 0.51 
Interaction (iT-CD8*iT-FOXP3) 0.82 0.53 1.27 0.38 
     
iT-CD8+ 0.90 0.61 1.31 0.57 
S-FOXP3+ 1.27 0.93 1.73 0.13 
Interaction (iT-CD8*S-FOXP3) 0.78 0.50 1.22 0.27 
     
S-CD8+ 0.66 0.49 0.89 0.006 
iT-FOXP3+ 0.78 0.53 1.17 0.23 
Interaction (S-CD8*iT-FOXP3) 1.26 0.79 1.99 0.33 
     
S-CD8+ 0.70 0.47 1.04 0.08 
S-FOXP3+ 1.22 0.82 1.82 0.32 
Interaction (S-CD8*S-FOXP3) 0.97 0.57 1.64 0.90 
 
 
 
Supplementary Table 13: Multivariate Cox-regression analysis based on the 
complete case analysis of iT-CD8+ cells in ER-positive HER2-positive breast 
cancer 
ER-POSITIVE, HER2-POSITIVE 
Variable Categories Subjects Events HR 95% CI P T 95% CI P 
Positive lymph nodes 0, 1, 2-4, 5-9, ≥10 
483 162 
1.31 1.17 1.47 <0.00001 
    
Tumour size 
<10mm, 10-19mm, 20-29mm, 
30-49mm, ≥50mm 1.33 1.12 1.58 0.001 
    Grade 1, 2, 3 2.37 0.93 6.07 0.07 0.62 0.33 1.18 0.15 
PR status Negative, Positive 0.46 0.21 1.03 0.06 1.63 0.90 2.94 0.10 
iT-CD8 Negative, Positive 0.69 0.50 0.94 0.02 
    † Variables which violated the proportional hazards assumption were accounted for by an extended Cox-model where the beta-coefficient 
varies linearly with the natural logarithm of time.  ‘T’ represents the exponentiated extended coefficient where a value >1 implies increasing 
hazard over time whereas a value of <1 implies decreasing hazard over time 
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Supplementary Figure 1 
Histograms illustrating the 
relative distributions of 
observed values and imputed 
values by variables included in 
the imputation model. 
Observed Values
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Supplementary Figure 2 
Kaplan-Meier survival plots of patient groups defined by whether data was missing or not missing for 
investigated markers. 
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Supplementary Figure 3 
Spine plots illustrating the percentage 
distributions of clinical and molecular 
characteristics by study.   
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Supplementary Figure 4 
Distribution of T-cell counts by study, histological type and molecular subtype illustrated as box-plots.  
Note T-cell counts for the BCCA study were capped at an upper limit of 100.
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1.09 (0.92, 1.29)
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0.91 (0.76, 1.09)
1.05 (0.88, 1.25)
1.08 (0.93, 1.24)
0.91 (0.62, 1.35)
0.86 (0.61, 1.21)
1.06 (0.85, 1.31)
1.01 (0.86, 1.19)
1.01 (0.88, 1.15)
0.93 (0.67, 1.30)
1.01 (0.87, 1.18)
0.89 (0.55, 1.44)
0.93 (0.67, 1.30)
HR (95% CI)
  
1.25 .5 2
Hazard ratio
ER positive (CCA)
Study
SEARCH
BCCA
NBCS
NEAT
Subtotal  (I-squared = 23.2%, p = 0.272)
Age
<55 years
>55 years
Subtotal  (I-squared = 74.4%, p = 0.048)
No. positive nodes
0
1
2 to 4
5 to 9
10+
Subtotal  (I-squared = 0.0%, p = 0.811)
Tumour size
<10mm
10-19mm
20-29mm
30-49mm
50+mm
Subtotal  (I-squared = 0.0%, p = 0.940)
Grade
2
3
Subtotal  (I-squared = 0.0%, p = 0.340)
Hormone therapy
No
Yes
Subtotal  (I-squared = 68.6%, p = 0.074)
Chemotherapy
No
Yes
Subtotal  (I-squared = 72.3%, p = 0.057)
Morphology
IDC-NST
Lobular
Medullary
Other
Subtotal  (I-squared = 5.1%, p = 0.368)
PR status
Negative
Positive
Subtotal  (I-squared = 0.0%, p = 0.664)
HER2 status
Negative
Positive
Subtotal  (I-squared = 0.0%, p = 0.439)
Molecular subtype
HER2
CBP
5NP
Subtotal  (I-squared = 61.5%, p = 0.074)
Subgroup
0.79 (0.52, 1.22)
0.92 (0.75, 1.13)
0.65 (0.42, 1.00)
0.66 (0.46, 0.94)
0.72 (0.58, 0.88)
0.98 (0.77, 1.24)
0.75 (0.58, 0.96)
0.81 (0.53, 1.24)
0.60 (0.43, 0.86)
0.81 (0.50, 1.30)
0.70 (0.41, 1.19)
0.45 (0.11, 1.82)
0.81 (0.53, 1.23)
0.80 (0.61, 1.05)
0.84 (0.65, 1.08)
0.79 (0.53, 1.18)
0.87 (0.57, 1.32)
0.70 (0.59, 0.83)
0.78 (0.63, 0.97)
1.09 (0.81, 1.48)
0.95 (0.71, 1.27)
0.68 (0.56, 0.82)
0.83 (0.70, 0.99)
0.85 (0.32, 2.27)
0.29 (0.08, 1.12)
1.02 (0.66, 1.58)
0.80 (0.68, 0.94)
0.89 (0.56, 1.41)
0.75 (0.63, 0.91)
0.86 (0.65, 1.15)
0.88 (0.65, 1.19)
0.59 (0.46, 0.76)
0.91 (0.60, 1.36)
HR (95% CI)
  
1.25 .5 2
Hazard ratio
ER negative (CCA)
Study
SEARCH
NBCS
NEAT
Subtotal  (I-squared = 77.6%, p = 0.012)
Age
<55 years
>55 years
Subtotal  (I-squared = 43.0%, p = 0.185)
No. positive nodes
0
1
2 to 4
5 to 9
10+
Subtotal  (I-squared = 0.0%, p = 0.835)
Tumour size
<10mm
10-19mm
20-29mm
30-49mm
50+mm
Subtotal  (I-squared = 0.0%, p = 0.765)
Grade
1
2
3
Subtotal  (I-squared = 53.9%, p = 0.114)
Hormone therapy
No
Yes
Subtotal  (I-squared = 0.0%, p = 0.740)
Chemotherapy
No
Yes
Subtotal  (I-squared = 80.8%, p = 0.022)
Morphology
IDC-NST
Lobular
Other
Subtotal  (I-squared = 11.5%, p = 0.323)
PR status
Negative
Positive
Subtotal  (I-squared = 0.0%, p = 0.652)
HER2 status
Negative
Positive
Subtotal  (I-squared = 60.2%, p = 0.113)
Molecular subtype
Luminal1a
Luminal1b
Luminal2
Subtotal  (I-squared = 26.3%, p = 0.258)
Subgroup
1.62 (1.19, 2.19)
1.59 (1.16, 2.18)
0.94 (0.72, 1.24)
1.18 (0.95, 1.48)
1.51 (1.13, 2.02)
1.29 (1.09, 1.54)
1.40 (0.99, 1.96)
1.43 (0.93, 2.21)
1.31 (0.93, 1.85)
1.05 (0.67, 1.64)
1.12 (0.62, 2.03)
1.00 (0.27, 3.65)
1.23 (0.85, 1.76)
1.35 (1.01, 1.81)
1.26 (0.89, 1.78)
0.82 (0.41, 1.63)
1.56 (0.69, 3.49)
1.26 (0.95, 1.67)
0.89 (0.71, 1.13)
1.70 (1.13, 2.56)
1.56 (1.20, 2.04)
1.60 (1.20, 2.14)
1.05 (0.84, 1.30)
1.17 (0.96, 1.44)
1.57 (0.95, 2.58)
1.66 (0.99, 2.77)
1.18 (0.83, 1.69)
1.30 (1.05, 1.60)
1.33 (1.08, 1.64)
0.94 (0.64, 1.37)
1.31 (1.05, 1.63)
1.52 (0.82, 2.80)
0.94 (0.64, 1.37)
HR (95% CI)
  
1.25 .5 2
Hazard ratio
ER positive
Study
SEARCH
NBCS
NEAT
Subtotal  (I-squared = 75.7%, p = 0.016)
Age
<55 years
>55 years
Subtotal  (I-squared = 27.9%, p = 0.239)
No. positive nodes
0
1
2 to 4
5 to 9
10+
Subtotal  (I-squared = 0.0%, p = 0.841)
Tumour size
<10mm
10-19mm
20-29mm
30-49mm
50+mm
Subtotal  (I-squared = 0.0%, p = 0.713)
Grade
1
2
3
Subtotal  (I-squared = 0.0%, p = 0.495)
Hormone therapy
No
Yes
Subtotal  (I-squared = 22.8%, p = 0.255)
Chemotherapy
No
Yes
Subtotal  (I-squared = 65.0%, p = 0.091)
Morphology
IDC-NST
Lobular
Medullary
Other
Subtotal  (I-squared = 0.0%, p = 0.931)
PR status
Negative
Positive
Subtotal  (I-squared = 0.0%, p = 0.572)
HER2 status
Negative
Positive
Subtotal  (I-squared = 51.1%, p = 0.153)
Molecular subtype
HER2
CBP
5NP
Subtotal  (I-squared = 5.8%, p = 0.346)
Subgroup
1.15 (0.83, 1.60)
0.99 (0.70, 1.40)
0.63 (0.47, 0.84)
0.80 (0.63, 1.00)
1.02 (0.72, 1.43)
0.85 (0.61, 1.17)
0.85 (0.50, 1.45)
0.81 (0.54, 1.22)
1.09 (0.66, 1.79)
1.13 (0.58, 2.20)
0.93 (0.30, 2.83)
0.94 (0.64, 1.39)
0.91 (0.66, 1.24)
0.71 (0.49, 1.02)
1.14 (0.60, 2.17)
0.58 (0.06, 5.13)
1.10 (0.63, 1.91)
0.78 (0.64, 0.95)
0.94 (0.68, 1.31)
1.26 (0.87, 1.81)
1.13 (0.75, 1.72)
0.76 (0.61, 0.93)
0.89 (0.73, 1.08)
1.07 (0.30, 3.86)
0.77 (0.15, 3.95)
1.10 (0.55, 2.21)
0.84 (0.69, 1.02)
0.69 (0.36, 1.32)
0.82 (0.65, 1.02)
1.10 (0.78, 1.55)
1.08 (0.75, 1.55)
0.75 (0.55, 1.04)
0.85 (0.57, 1.27)
HR (95% CI)
  
1.25 .5 2
Hazard ratio
ER negative
Study
SEARCH
NBCS
NEAT
Subtotal  (I-squared = 82.2%, p = 0.004)
Age
<55 years
>55 years
Subtotal  (I-squared = 23.2%, p = 0.254)
No. positive nodes
0
1
2 to 4
5 to 9
10+
Subtotal  (I-squared = 0.0%, p = 0.422)
Tumour size
<10mm
10-19mm
20-29mm
30-49mm
50+mm
Subtotal  (I-squared = 35.2%, p = 0.186)
Grade
1
2
3
Subtotal  (I-squared = 71.0%, p = 0.032)
Hormone therapy
No
Yes
Subtotal  (I-squared = 0.0%, p = 0.787)
Chemotherapy
No
Yes
Subtotal  (I-squared = 79.6%, p = 0.027)
Morphology
IDC-NST
Lobular
Medullary
Other
Subtotal  (I-squared = 65.4%, p = 0.056)
PR status
Negative
Positive
Subtotal  (I-squared = 0.0%, p = 0.350)
HER2 status
Negative
Positive
Subtotal  (I-squared = 61.9%, p = 0.105)
Molecular subtype
Luminal1a
Luminal1b
Luminal2
Subtotal  (I-squared = 33.3%, p = 0.223)
Subgroup
1.91 (1.34, 2.71)
1.60 (1.16, 2.22)
0.90 (0.66, 1.23)
1.21 (0.94, 1.55)
1.52 (1.12, 2.07)
1.61 (1.07, 2.42)
1.70 (1.05, 2.77)
1.57 (1.07, 2.29)
0.89 (0.51, 1.54)
1.51 (0.76, 2.99)
0.35 (0.04, 3.03)
1.28 (0.87, 1.88)
1.53 (1.12, 2.08)
1.26 (0.86, 1.85)
0.61 (0.28, 1.32)
2.34 (1.01, 5.41)
1.32 (0.95, 1.83)
0.89 (0.69, 1.15)
1.89 (1.21, 2.95)
1.76 (1.32, 2.34)
1.73 (1.28, 2.36)
1.11 (0.86, 1.42)
1.16 (0.92, 1.45)
2.23 (1.30, 3.83)
1.00 (1.00, 1.00)
1.70 (0.99, 2.94)
1.10 (0.74, 1.65)
1.38 (1.10, 1.73)
1.37 (1.09, 1.71)
0.92 (0.61, 1.40)
1.28 (0.98, 1.68)
1.77 (0.90, 3.48)
0.92 (0.61, 1.40)
HR (95% CI)
  
1.25 .5 2
Hazard ratio
ER positive (CCA)
Study
SEARCH
NBCS
NEAT
Subtotal  (I-squared = 78.8%, p = 0.009)
Age
<55 years
>55 years
Subtotal  (I-squared = 0.0%, p = 0.381)
No. positive nodes
0
1
2 to 4
5 to 9
10+
Subtotal  (I-squared = 0.0%, p = 0.645)
Tumour size
<10mm
10-19mm
20-29mm
30-49mm
50+mm
Subtotal  (I-squared = 0.0%, p = 0.432)
Grade
1
2
3
Subtotal  (I-squared = 0.0%, p = 0.598)
Hormone therapy
No
Yes
Subtotal  (I-squared = 0.0%, p = 0.339)
Chemotherapy
No
Yes
Subtotal  (I-squared = 67.5%, p = 0.080)
Morphology
IDC-NST
Lobular
Medullary
Other
Subtotal  (I-squared = 0.0%, p = 0.987)
PR status
Negative
Positive
Subtotal  (I-squared = 0.0%, p = 0.360)
HER2 status
Negative
Positive
Subtotal  (I-squared = 89.8%, p = 0.002)
Molecular subtype
HER2
CBP
5NP
Subtotal  (I-squared = 79.1%, p = 0.008)
Subgroup
1.23 (0.81, 1.85)
0.99 (0.69, 1.42)
0.57 (0.41, 0.79)
0.77 (0.59, 1.00)
0.94 (0.65, 1.37)
0.82 (0.55, 1.21)
0.84 (0.47, 1.49)
0.70 (0.42, 1.19)
1.17 (0.62, 2.21)
1.25 (0.59, 2.66)
0.73 (0.18, 2.92)
0.94 (0.59, 1.50)
0.94 (0.66, 1.35)
0.60 (0.40, 0.90)
1.13 (0.51, 2.52)
0.95 (0.10, 9.23)
1.14 (0.59, 2.23)
0.79 (0.63, 1.01)
1.00 (0.68, 1.46)
1.33 (0.85, 2.09)
1.17 (0.74, 1.84)
0.73 (0.57, 0.94)
0.91 (0.72, 1.14)
0.84 (0.10, 7.28)
0.66 (0.13, 3.42)
0.89 (0.39, 2.07)
0.83 (0.65, 1.04)
0.59 (0.29, 1.18)
0.69 (0.53, 0.89)
1.48 (0.99, 2.20)
1.48 (0.98, 2.25)
0.66 (0.45, 0.97)
0.64 (0.38, 1.08)
HR (95% CI)
  
1.25 .5 2
Hazard ratio
ER negative (CCA)
Study
SEARCH
NBCS
NEAT
Subtotal  (I-squared = 47.6%, p = 0.148)
Age
<55 years
>55 years
Subtotal  (I-squared = 0.0%, p = 0.741)
No. positive nodes
0
1
2 to 4
5 to 9
10+
Subtotal  (I-squared = 0.0%, p = 0.682)
Tumour size
<10mm
10-19mm
20-29mm
30-49mm
50+mm
Subtotal  (I-squared = 0.0%, p = 0.865)
Grade
1
2
3
Subtotal  (I-squared = 0.0%, p = 0.697)
Hormone therapy
No
Yes
Subtotal  (I-squared = 56.5%, p = 0.130)
Chemotherapy
No
Yes
Subtotal  (I-squared = 60.7%, p = 0.111)
Morphology
IDC-NST
Lobular
Other
Subtotal  (I-squared = 0.0%, p = 0.706)
PR status
Negative
Positive
Subtotal  (I-squared = 0.0%, p = 0.452)
HER2 status
Negative
Positive
Subtotal  (I-squared = 79.0%, p = 0.029)
Molecular subtype
Luminal1a
Luminal1b
Luminal2
Subtotal  (I-squared = 57.8%, p = 0.094)
Subgroup
1.02 (0.78, 1.32)
1.38 (1.01, 1.87)
0.92 (0.70, 1.22)
1.10 (0.90, 1.34)
1.04 (0.80, 1.34)
1.19 (0.90, 1.59)
1.07 (0.70, 1.62)
0.92 (0.68, 1.24)
0.94 (0.63, 1.40)
0.84 (0.47, 1.48)
1.26 (0.49, 3.25)
1.21 (0.89, 1.64)
1.03 (0.80, 1.34)
1.02 (0.74, 1.42)
0.87 (0.48, 1.60)
1.16 (0.66, 2.05)
0.90 (0.70, 1.14)
0.90 (0.71, 1.13)
1.51 (0.99, 2.30)
1.04 (0.83, 1.31)
1.19 (0.93, 1.53)
0.92 (0.75, 1.13)
1.01 (0.83, 1.23)
1.06 (0.71, 1.59)
1.24 (0.80, 1.91)
0.96 (0.70, 1.33)
1.11 (0.92, 1.34)
1.09 (0.91, 1.30)
0.68 (0.46, 1.00)
1.09 (0.90, 1.31)
1.07 (0.61, 1.89)
0.68 (0.46, 1.00)
HR (95% CI)
  
1.25 .5 2
Hazard ratio
ER positive
Study
SEARCH
NBCS
NEAT
Subtotal  (I-squared = 12.3%, p = 0.320)
Age
<55 years
>55 years
Subtotal  (I-squared = 0.0%, p = 0.556)
No. positive nodes
0
1
2 to 4
5 to 9
10+
Subtotal  (I-squared = 0.0%, p = 0.856)
Tumour size
<10mm
10-19mm
20-29mm
30-49mm
50+mm
Subtotal  (I-squared = 0.0%, p = 0.632)
Grade
1
2
3
Subtotal  (I-squared = 26.7%, p = 0.256)
Hormone therapy
No
Yes
Subtotal  (I-squared = 0.0%, p = 0.989)
Chemotherapy
No
Yes
Subtotal  (I-squared = 6.5%, p = 0.301)
Morphology
IDC-NST
Lobular
Other
Subtotal  (I-squared = 0.0%, p = 0.590)
PR status
Negative
Positive
Subtotal  (I-squared = 46.2%, p = 0.173)
HER2 status
Negative
Positive
Subtotal  (I-squared = 0.0%, p = 0.321)
Molecular subtype
HER2
CBP
5NP
Subtotal  (I-squared = 0.0%, p = 0.950)
Subgroup
1.10 (0.78, 1.55)
1.00 (0.65, 1.56)
0.78 (0.58, 1.06)
0.97 (0.77, 1.22)
0.85 (0.59, 1.24)
0.92 (0.66, 1.29)
1.11 (0.63, 1.96)
0.75 (0.49, 1.16)
0.98 (0.59, 1.61)
0.92 (0.47, 1.82)
2.24 (0.40, 12.51)
0.98 (0.65, 1.48)
0.95 (0.66, 1.35)
0.85 (0.60, 1.21)
1.39 (0.72, 2.67)
0.41 (0.08, 2.08)
1.20 (0.75, 1.92)
0.84 (0.67, 1.05)
1.06 (0.73, 1.54)
1.06 (0.73, 1.56)
1.11 (0.73, 1.70)
0.87 (0.69, 1.08)
0.90 (0.73, 1.11)
0.74 (0.22, 2.49)
1.39 (0.59, 3.30)
0.87 (0.71, 1.07)
1.39 (0.73, 2.63)
0.97 (0.76, 1.24)
0.78 (0.56, 1.10)
0.81 (0.57, 1.15)
0.88 (0.62, 1.25)
0.83 (0.55, 1.27)
HR (95% CI)
  
1.25 .5 2
Hazard ratio
ER negative
Study
SEARCH
NBCS
NEAT
Subtotal  (I-squared = 28.7%, p = 0.246)
Age
<55 years
>55 years
Subtotal  (I-squared = 0.0%, p = 0.811)
No. positive nodes
0
1
2 to 4
5 to 9
10+
Subtotal  (I-squared = 0.0%, p = 0.808)
Tumour size
<10mm
10-19mm
20-29mm
30-49mm
50+mm
Subtotal  (I-squared = 0.0%, p = 0.653)
Grade
1
2
3
Subtotal  (I-squared = 36.3%, p = 0.208)
Hormone therapy
No
Yes
Subtotal  (I-squared = 74.2%, p = 0.049)
Chemotherapy
No
Yes
Subtotal  (I-squared = 52.3%, p = 0.148)
Morphology
IDC-NST
Lobular
Other
Subtotal  (I-squared = 0.0%, p = 0.547)
PR status
Negative
Positive
Subtotal  (I-squared = 14.0%, p = 0.281)
HER2 status
Negative
Positive
Subtotal  (I-squared = 49.8%, p = 0.158)
Molecular subtype
Luminal1a
Luminal1b
Luminal2
Subtotal  (I-squared = 0.0%, p = 0.455)
Subgroup
0.99 (0.73, 1.34)
1.34 (0.97, 1.85)
0.94 (0.69, 1.28)
1.09 (0.87, 1.37)
1.05 (0.79, 1.39)
1.13 (0.79, 1.63)
0.82 (0.51, 1.30)
0.95 (0.67, 1.35)
0.87 (0.55, 1.40)
0.81 (0.41, 1.63)
1.34 (0.37, 4.93)
1.25 (0.89, 1.76)
0.98 (0.74, 1.30)
1.11 (0.76, 1.60)
0.73 (0.37, 1.46)
1.71 (0.85, 3.42)
0.88 (0.67, 1.16)
0.91 (0.70, 1.18)
1.60 (1.01, 2.54)
0.94 (0.73, 1.22)
1.16 (0.88, 1.52)
0.88 (0.70, 1.12)
0.99 (0.80, 1.23)
1.16 (0.72, 1.86)
1.30 (0.82, 2.08)
0.90 (0.63, 1.30)
1.14 (0.93, 1.40)
1.06 (0.87, 1.30)
0.75 (0.48, 1.16)
1.03 (0.82, 1.30)
1.00 (0.51, 1.95)
0.75 (0.48, 1.16)
HR (95% CI)
  
1.25 .5 2
Hazard ratio
ER positive (CCA)
Study
SEARCH
NBCS
NEAT
Subtotal  (I-squared = 35.5%, p = 0.212)
Age
<55 years
>55 years
Subtotal  (I-squared = 8.1%, p = 0.297)
No. positive nodes
0
1
2 to 4
5 to 9
10+
Subtotal  (I-squared = 0.0%, p = 0.889)
Tumour size
<10mm
10-19mm
20-29mm
30-49mm
50+mm
Subtotal  (I-squared = 0.0%, p = 0.515)
Grade
1
2
3
Subtotal  (I-squared = 60.3%, p = 0.081)
Hormone therapy
No
Yes
Subtotal  (I-squared = 0.0%, p = 0.928)
Chemotherapy
No
Yes
Subtotal  (I-squared = 0.0%, p = 0.629)
Morphology
IDC-NST
Other
Subtotal  (I-squared = 0.0%, p = 0.397)
PR status
Negative
Positive
Subtotal  (I-squared = 37.9%, p = 0.204)
HER2 status
Negative
Positive
Subtotal  (I-squared = 0.0%, p = 0.556)
Molecular subtype
HER2
CBP
5NP
Subtotal  (I-squared = 0.0%, p = 0.434)
Subgroup
1.32 (0.88, 1.99)
1.05 (0.65, 1.68)
0.82 (0.58, 1.16)
1.09 (0.82, 1.45)
0.84 (0.56, 1.26)
0.94 (0.62, 1.43)
1.23 (0.64, 2.38)
0.86 (0.49, 1.50)
1.21 (0.60, 2.42)
0.88 (0.40, 1.92)
2.74 (0.34, 21.84)
0.98 (0.59, 1.64)
1.04 (0.70, 1.53)
0.90 (0.59, 1.38)
1.83 (0.83, 4.06)
0.54 (0.10, 2.84)
1.87 (1.01, 3.45)
0.91 (0.70, 1.18)
1.16 (0.74, 1.82)
1.19 (0.74, 1.91)
1.09 (0.65, 1.83)
0.94 (0.72, 1.23)
0.98 (0.76, 1.26)
1.52 (0.57, 4.03)
0.95 (0.74, 1.22)
1.54 (0.76, 3.12)
1.05 (0.79, 1.39)
0.90 (0.57, 1.41)
1.01 (0.62, 1.63)
1.10 (0.70, 1.71)
0.71 (0.42, 1.19)
HR (95% CI)
  
1.25 .5 2
Hazard ratio
ER negative (CCA)
iT-CD8
No chemotherapy
Chemotherapy
Subtotal  (I-squared = 0.0%, p = 0.443)
S-CD8
No chemotherapy
Chemotherapy
Subtotal  (I-squared = 0.0%, p = 0.569)
iT-FOXP3
No chemotherapy
Chemotherapy
Subtotal  (I-squared = 0.0%, p = 0.720)
S-FOXP3
No chemotherapy
Chemotherapy
Subtotal  (I-squared = 0.0%, p = 0.887)
Subgroup
0.74 (0.57, 0.97)
0.66 (0.56, 0.78)
0.77 (0.57, 1.02)
0.69 (0.58, 0.82)
0.95 (0.62, 1.46)
0.87 (0.69, 1.08)
0.93 (0.60, 1.43)
0.90 (0.72, 1.12)
HR (95% CI)
  1.5 1.5
iT-CD8
No chemotherapy
Chemotherapy
Subtotal  (I-squared = 0.0%, p = 0.580)
S-CD8
No chemotherapy
Chemotherapy
Subtotal  (I-squared = 0.0%, p = 0.451)
iT-FOXP3
No chemotherapy
Chemotherapy
Subtotal  (I-squared = 0.0%, p = 0.785)
S-FOXP3
No chemotherapy
Chemotherapy
Subtotal  (I-squared = 0.0%, p = 0.413)
Subgroup
0.72 (0.53, 1.00)
0.65 (0.54, 0.79)
0.71 (0.51, 0.99)
0.62 (0.51, 0.75)
1.05 (0.61, 1.80)
0.96 (0.72, 1.28)
0.80 (0.42, 1.51)
1.07 (0.80, 1.45)
HR (95% CI)
  1.5 1.5
Hazard ratio
CCA
SEARCH
No
Yes
Subtotal  (I-squared = 0.0%, p = 0.804)
BCCA
No
Yes
Subtotal  (I-squared = 0.0%, p = 0.862)
NBCS
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Supplementary Figure 17
Trends in hazard ratios and 95% confidence intervals for T-cell status according to tumour proliferation and diagnosis age.  Estimates 
are adjusted for tumour size, histological grade and positive axillary lymph nodes.  Analyses are based on imputed data.  Estimates 
and confidence intervals associated with iT-CD8+ cells are represented as dark blue, those with S-CD8+ as light blue, those with iT-
FOXP3+ as dark red and those with S-FOXP3+ as light red.  Box sizes are proportional to the number of subjects in each subgroup.     
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